Sangui BioTech: Laboratorios Silanes Start Marketing Granulox in Mexico
03 11월 2014 - 8:56PM
Business Wire
Applications for licensing in all Central
American countries under way
Laboratorios Silanes (www.silanes.com.mx) commenced with the
marketing of the dressing material Granulox in Mexico on November
1, 2014, based on an exclusive agreement with SastoMed GmbH. At the
same time, Silanes has taken over the distribution for the
remaining countries of Central America and is currently applying
for the necessary certifications in the respective individual
markets. To be ready for the start of distribution, Silanes
ordered, received and paid for merchandise in the previous quarter,
which was reflected in a considerable five-digit license income by
Sangui as of 30 September 2014.
Laboratorios Silanes was founded in 1943 and, with a workforce
of around 700 employees, today ranks among the leading mid-sized
pharmaceutical companies of Central America and in terms of
revenues occupies third place in the league of the highest-volume
suppliers of products suitable for diabetics.
Prior to the start of the distribution, 250 sales
representatives took part in a training event which also included
an in-depth presentation by Michael Sander, Chief Executive Officer
of SastoMed GmbH, the global licensee for the sale of Granulox. The
sales force was introduced to the mode of action and the
application in a series of detailed scientific and practical
presentations, and given the marketing goals and materials.
"The start to marketing by Silanes concludes intensive
preliminary work which took two years and the restructuring of our
Mexico business", explained Michael Sander. "Thanks to the support
of BioMac CEO John McArdle, we now have gained a highly
professional partner in Silanes which has the market position to
leverage the public profile of Granulox locally and to translate it
into tangible success."
Antonio Lopez de Silanes, jr., the owner of Laboratorios
Silanes, explained at a national sales congress organized by his
company that Granulox had the potential for developing into a core
component of the product portfolio. He anticipates that the
investments in pre-marketing and marketing will soon pay off.
Sangui BioTech International, Inc. ("SGBI") is a holding company
the shares of which are being traded on the OTCQB marketplace
(www.otcmarkets.com: SGBI) and the OTC markets of Berlin and
Hamburg-Hannover stock exchanges. Its purpose is to provide
financing and access to the capital markets for the enterprises of
the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary
of Sangui BioTech International, Inc.
Sangui BioTech International, Inc.Joachim Fleing, Phone:
+49 (179) 7963472Fax: +49 (2302) 915191e-mail: fleing@sangui.de
Sangui Biotech (CE) (USOTC:SGBI)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Sangui Biotech (CE) (USOTC:SGBI)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
